Impact of renin-angiotensin-aldosterone system genes on the treatment response of patients with hypertension and metabolic syndrome

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 8, Issue 4, 2007, Pages 181-189

  Milionis, Haralampos J ^a   Kostapanos, Michael S ^a   Vakalis, Konstantinos ^a   Theodorou, Ioanna ^a   Bouba, Ioanna ^b   Kalaitzidis, Rigas ^a   Georgiou, Ioannis ^b   Elisaf, MosesS ^a   Siamopoulos, Kostas C ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Essential hypertension; Metabolic syndrome; Renin angiotensin aldosterone system genes; Response to treatment

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOCHEMICAL MARKER; CALCIUM ANTAGONIST; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGE; AGED; ALLELE; ANTHROPOMETRY; ARTICLE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; GENETIC MARKER; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METABOLIC PARAMETERS; METABOLIC SYNDROME X; PULSE PRESSURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

DEMOGRAPHY; FEMALE; GENOTYPE; GREECE; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POLYMORPHISM, GENETIC; PREVALENCE; REGRESSION ANALYSIS; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 38649099731     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2007.027     Document Type: Article

References (42)

1. Malik S, Wong ND, Franklin SS et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110:1245-50.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
3. Gazi I, Liberopoulos E, Mikhailidis DP, Elisaf M. Metabolic syndrome: clinical features leading to therapeutic strategies. Vasc Dis Prev 2004;1:243-53.
4. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
5. Grundy SM, Cleeman JI, Daniels SR et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52.
6. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-62.
7. Liberopoulos E, Elisaf M. Diagnosis of the metabolic syndrome: which definition should we use? Hell J Cardiol 2005;46:258-62.
8. Barnett AH, Bain SC, Bouter P et al. Diabetics exposed to telmisartan and enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-61.
9. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004;64:2537-65.
10. Strazzullo P, Galletti F. Impact of the renin-angiotensin system on lipid and carbohydrate metabolism. Curr Opin Nephrol Hypertens 2004;13:325-32.
11. Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 2004; 44:12-19.
12. Li X, Du Y, Du Y, Huang X. Correlation of angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol Ther 2003;8:25-30.
13. Dieguez-Lucena JL, Aranda-Lara P, Ruiz-Galdon M, Garcia-Villanova J, Morell-Ocana M, Reyes-Engel A. Angiotensin I-converting enzyme genotypes and angiotensin II receptors. Response to therapy. Hypertension 1996;28:98-103.
14. Mondorf UF, Russ A, Wiesemann A, Herrero M, Oremek G, Lenz T. Contribution of angiotensin I converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension. Am J Hypertens 1998;11:174-83.
15. Kurland L, Melhus H, Karlsson J et al. Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) Trial. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001;19:1783-7.
16. Baudin B. Angiotensin I-converting enzyme gene polymorphism and drug response. Clin Chem Lab Med 2000; 38:853-6.
17. Chobanian AV, Bakris GL, Black HR et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-72.
18. Milionis HJ, Papakostas J, Kakafika A, Chasiotis G, Seferiadis K, Elisaf MS. Comparative effects of atorvastatin, simvastatin and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J Clin Pharmacol 2003; 43:825-30.
19. Cockroft DW, Gault MH. Prediction of creatinine clearance form serum creatinine. Nephron 1976;16:31-9.
20. Russ AP, Maerz W, Ruzicka V, Stein U, Gross W. Rapid detection of hypertension-associated Met235 - Thr allele of the human angiotensinogen gene. Hum Mol Gen 1993;2:609-10.
21. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I converting enzyme levels. J Clin Invest 1990; 86:1343-6.
22. Bonnardeaux A, Davies E, Jeunemaitre X et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994;24:63-9.
23. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000; 35:1270-7.
24. Massiera F, Seydoux J, Geloen A et al. Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology 2001;142:5220-5.
25. Goossens GH, Blaak EE, van Baak MA. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev 2003;4:43-55.
26. Nickenig G, Roling J, Strehlow K, Schnabel P, Bohm M. Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation 1998; 98:2453-60.
27. Nakai K, Itoh C, Miura Y et al. Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with serum ACE concentration and increased risk for CAD in the Japanese. Circulation 1994;90:2199-202.
28. Lachurie ML, Azizi M, Guyene TT, Alhenc-Gelas F, Menard J. Angiotensin converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. Circulation 1995;91:2933-42.
29. Castellano M, Muiesan ML, Rizzoni D et al. Angiotensin-converting enzyme I/D polymorphism and arterial wall thickness in a general population. The Vobarno Study. Circulation 1995;91:2721-4.
30. Paillard F, Chansel D, Brand E et al. Genotype-Phenotype Relationships for the Renin-Angiotensin-Aldosterone System in a Normal Population. Hypertension 1999;34:423-9.
31. Thomas GN, Tomlinson B, Chan JC, Sanderson JE, Cockram CS, Critchley JA. Renin-angiotensin system gene polymorphisms, blood pressure, dyslipidemia, and diabetes in Hong Kong Chinese: a significant association of the ACE insertion/deletion polymorphism with type 2 diabetes. Diabetes Care 2001;24:356-61.
32. Katsuya T, Horiuchi M, Chen YDI et al. Relation between deletion polymorphism of the angiotensin-converting enzyme gene and insulin resistance, glucose intolerance, hyperinsulinemia and dislipidemia. Arterioscler Thromb Vasc Biol 1995;15:779-82.
33. Chiu KC, McCarthy JE. The insertion allele at the angiotensin I-converting enzyme gene locus is associated with insulin resistance. Metabolism 1997;46:395-9.
34. Panahloo A, Andres C, Mohamed-Ali V et al. The insertion allele of the ACE gene I/D polymorphism: a candidate gene for insulin resistance? Circulation 1995;92:3390-3.
35. Williams RR, Hunt SC, Hopkins PN et al. Genetic basis of familial dyslipidemia and hypertension: 15-year results from Utah. Am J Hypertens 1993;6:319S-327S.
36. Nagi DK, Foy CA, Mohamed-Ali V, Yudkin JS, Grant PJ, Knowler WC. Angiotensin-1-converting enzyme (ACE) gene polymorphism, plasma ACE levels, and their association with the metabolic syndrome and electrocardiographic coronary artery disease in Pima Indian. Metabolism 1998;47:622-6.
37. del Ser T, Bornstein B, Barba R, Cemillan C. Relationship of angiotensin converting enzyme genotype with serum triglyceride concentration in stroke patients. Neurosci Lett 2001;316:21-4.
38. Lee YJ, Tsai JC. ACE gene insertion/deletion polymorphism associated with 1998 World Health Organization definition of metabolic syndrome in Chinese type 2 diabetic patients. Diabetes Care 2002; 25:1002-08.
39. Frazier L, Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic. Pharmacogenom J 2004; 4:17-23.
40. Benetos A, Gautier S, Ricard S et al. Influence of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. Circulation 1996;94:698-703.
41. Castellano M, Muiesan ML, Beschi M et al. Angiotensin II type 1 receptor A/C1166 polymorphism: relationships with blood pressure and cardiovascular structure. Hypertension 1996;28:1076-80.
42. Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003;107:2864-9.